Literature DB >> 2032900

State-of-the-art of external photon beam radiation treatment planning. Photon Treatment Planning Collaborative Working Group.

.   

Abstract

A virtual revolution in computer capability has occurred in the last few years, largely based on rapidly decreasing costs and increasing reliability of digital memory and mass-storage capability. These developments have now made it possible to consider the application of both computer and display technologies to a much broader range of problems in radiation therapy, including planning of treatment, dose computation, and treatment verification. Several methods of three-dimensional dose computations in heterogeneous media capable of 3% accuracy are likely to be available, but significant work still remains, particularly for high energy x-rays where electron transport, and possibly pair production, need to be considered. Innovative display and planning techniques, as well as plan evaluation schemes, are emerging and show great promise for the future. No doubt these advances will lead to substantially improved treatment planning systems in the next few years. However, it must be emphasized that for many of these applications a tremendous software and hardware development effort is required.

Entities:  

Mesh:

Year:  1991        PMID: 2032900     DOI: 10.1016/0360-3016(91)90164-y

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process.

Authors:  Matthew J Krasin; Melissa M Hudson; Sue C Kaste
Journal:  Pediatr Radiol       Date:  2004-01-27

Review 2.  The use of medical images in planning and delivery of radiation therapy.

Authors:  I J Kalet; M M Austin-Seymour
Journal:  J Am Med Inform Assoc       Date:  1997 Sep-Oct       Impact factor: 4.497

3.  Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk.

Authors:  Steve Braunstein; Jean L Nakamura
Journal:  Front Oncol       Date:  2013-04-03       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.